Clinical Trial Enrichment Could Require Post-Market Studies, Labeling To Address Shortcomings
This article was originally published in The Pink Sheet Daily
FDA’s guidance on clinical trial enrichment notes that a lack of information on patients without the enrichment characteristic may result in Phase IV studies to characterize a drug’s safety and efficacy in a broader population.
You may also be interested in...
Portola says that it does not expect it will need to do a second Phase III study to get FDA approval for betrixaban, after missing major endpoint in APEX, but analysts have doubts.
Without clear-cut evidence that a drug will not work in patients without a predictive marker, enrichment strategies should allow for collecting some data in the marker-negative population, FDA says in draft guidance.
FDA is showing for the second time in as many weeks that all things are possible when it comes to clearing targeted oncologics with compelling evidence. The agency cleared Pfizer’s Xalkori (crizotinib) for late-stage non-small cell lung cancer Aug. 26, just under five months from submission and based on early stage evidence.